We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Leukemic Stem Cell (CD34+/CD38-/TIM3+) Frequency in Patients with Acute Myeloid Leukemia: Clinical Implications.
- Authors
M.I. Mohamed, Mahmoud; Aref, Salah; Al Agdar, Mohamed; Mabed, Mohamed; El-Sokkary, Ahmed M.A.
- Abstract
This study aimed to address the prognostic relevance of CD34+/CD38–/TIM3+ leukemic stem cell (LSC) frequency in patients with acute myeloid leukemia (AML) and its impact on patient outcome. We analyzed the expression of LSC markers (CD34+/CD38–/TIM3+) using flow cytometry in bone marrow samples of 53 AML cases before and after induction chemotherapy. The LSC frequency at diagnosis was significantly higher compared with that postinduction (P <.001). Patients were categorized into high LSC expressers (≥ median) and low expressers (< median). Patients with AML with high number of LSCs at diagnosis had significantly lower induction of remission response (P =.0104), shorter disease-free survival, and shorter overall survival (P <.001 for both) compared with those with lower LSC count. Cox regression analysis revealed that LSC frequency at diagnosis is an independent prognostic factor in AML. Assessment of LSCs (CD34+/CD38–/TIM3+) at diagnosis is recommended for refining of AML risk stratification. The leukemic stem cell (LSC) frequency at diagnosis was significantly higher compared with that postinduction. Patients with acute myeloid leukemia (AML) with a higher number of LSCs at diagnosis have significantly lower induction of remission response, shorter disease-free survival, and shorter overall survival compared with those with lower LSC count. Assessment of LSCs (CD34+/CD38–/TIM3+) at diagnosis is recommended for refining of AML risk stratification.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, Issue 8, p508
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2021.03.009